COVID-19 Therapeutics – Product Information

Texas Case Counts microscopic example of a coronavirus

This page contains product-specific information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact therapeutics@dshs.texas.gov or call Provider Support at 833‑832‑7068, option 0.


Bebtelovimab (Lilly)


Bamlanivimab and Etesevimab (Lilly)

Note: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab when given alone


Casirivimab/Imdevimab (Regeneron)


Sotrovimab (GlaxoSmithKline)


Evusheld (tixagevimab co-packaged with cilgavimab) (AstraZeneca)


Lagevrio (molnupiravir) (Merck)


Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) (Pfizer)

▲ Top


This page is being updated as new information becomes available.

Last updated September 16, 2022